A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic…
Articles by Andrea Lobo, PhD
A cystic fibrosis (CF) therapy slightly but significantly increased diversity in the lung microbiome, the community of microorganisms found…
A clinical trial assessing the safety and tolerability of CMTX-101, an antibody-based therapy for cystic fibrosis (CF) lung infections,…
The abundance of Pseudomonas bacteria and related virulence factors in the lungs of people with cystic fibrosis (CF) after…
The 10th Annual Glow Ride for Cystic Fibrosis (CF), held Sept. 21 at Hermosa Beach, California, exceeded expectations by…
An agency of the National Institutes of Health has awarded funding up to $7 million to researchers at the University…
Lung function decline slowed consistently over five years with Kalydeco (ivacaftor) treatment in adults and children with cystic…
More severe lung disease and using inhaled corticosteroids are associated with shorter telomere length, a sign of cellular aging, in…
Most people with cystic fibrosis (CF) who carry mutations that make them ineligible for CFTR modulators are prescribed medications…
Having COVID-19 had no clinically meaningful impact on lung function and nutritional status for people with cystic fibrosis in…